News

MNG Expands Global Reach with Several New Distributors

MNG Laboratories is pleased to announce the signing of several key international distributor agreements in Asia, Latin America and Eastern Europe. MNG now has active distributors representing our extensive menu of over 500 neurogenetic and biochemical tests in Mexico, Hong Kong, Turkey and Chile. Each distributor was chosen for their clinical expertise, excellent customer service, […]


Introducing the MNG Xpress™ Actionable Epilepsy Panel

MNG is now launching the MNG Xpress™ Actionable Epilepsy panel with a standard STAT turnaround time of < 2 weeks at no additional cost and with no additional requisition forms to fill out. Our Actionable Epilepsy panel is now always STAT. You know MNG as your source for Neurogenetic Answers™ and we pride ourselves on delivering actionable results you can […]


Significant Improvements Made to Our Dystonia Panel Portfolio

We are pleased to announce that we have made substantial improvements in our ability to search for and identify the known pathogenic variants likely to cause dystonia. Our Comprehensive Dystonia Panel now includes 192 genes and 5,048 pathogenic variants associated with conditions linked to dystonia. This panel includes mtDNA sequencing and deletion analysis with the option of adding HTT repeat […]


The Most Comprehensive Exome Available

Now Covering 100% of Expert Approved Pathogenic Variants We are proud to announce that our MNG Exome™ now covers all pathogenic variants that are practice guideline and expert panel reviewed in ClinVar. These include variants located in intronic regions that are not covered by standard exome sequencing. In addition to sequencing, we include copy number analysis, mitochondrial genome […]


Webinar: Use of RNA Sequencing to Improve Diagnostic Sensitivity: What You Need to Know

Next-generation sequencing has evolved into a powerful tool helping thousands get molecular diagnosis of their conditions. In some cases, proving that a specific variant is the cause of a condition can be challenging or impossible based on information available in the literature. This is especially true for variants near intron-exon junctions. Similarly the splicing consequences […]


MNG Laboratories Announces New Scientific Advisory Board Members

(from left to right): Kevin Campbell, Terry Conrad, Peter Nagy, Val Sheffield, Uta Francke, Ben Tycko, Howard Worman, Keith Hyland MNG’s Scientific Advisory Board MNG Laboratories, a globally recognized clinical diagnostic leader specializing in neurogenetic and complex biochemical testing, is pleased to announce the appointment of five distinguished members of the genetic community to its […]


MNG Laboratories Welcomes Humberto Huerta, Sr. Director of Business Development

Humberto Huerta Senior Director of Business Development MNG Laboratories, a globally recognized clinical diagnostic leader specializing in neurogenetic and complex biochemical testing, is pleased to announce the appointment of Humberto Huerta as Senior Director of Business Development. Mr. Huerta brings 27 years of experience in the genetic/diagnostic testing field and will lead MNG’s expansion into […]


ASHG 2017 Summary

Featured Presentation MNG Laboratories’ Chief Medical Officer, Dr. Peter L. Nagy, MD, PhD, gave an insightful presentation on exome use in carrier testing. In a review of our data, we found that over 40% of children born with catastrophic or severe disabilities that we diagnosed with rare autosomal recessive conditions carry pathogenic variants that would […]


Webinar: Exome Use in Carrier Testing

In a review of our data, we found that over 40% of children born with catastrophic or severe disabilities that we diagnosed with rare autosomal recessive conditions carry pathogenic variants that would not have been detected using currently available targeted carrier tests. Join MNG Laboratories’ CMO, Dr. Peter L. Nagy, MD, PhD, as he discusses how the […]


Now Introducing RNA Sequencing Services

MNG Transcriptome™ is a cutting-edge, powerful analysis tool using RNA sequencing to determine what effect, if any, a VUS may have on the transcription of RNA from DNA, especially those found in splice site regions. This analysis is commonly used in cancer diagnostics, but can be applied to any phenotype to assess the functional impact […]